A series of clinical trial results in repurposing already-commercialized drugs for COVID-19 treatment is unveiling one by one, and the outcome seems to be contrasting among the pharmaceutical companies.

For some pharmaceutical companies, their highly anticipated clinical trials have failed and the results are affecting different drugs by other companies.

The companies without an outcome, yet, are busy covering up the market’s anxiety and concern by presenting interim status report or requesting for authorization.

# According to pharmaceutical industry sources on Mar. 9, Il-yang Pharmaceutical broke the news that it became the first South Korean company to have failed t